Articles tagged with Tuberculosis
Researchers at McGill University have identified a gene, NRAMP1, that controls the speed of tuberculosis development. The study found that variants of this gene affect the time frame between initial infection and disease progression.
A recent survey in Botswana has found a significant increase in drug-resistant tuberculosis, with 10% of new patients showing resistance to at least one anti-TB drug. The study suggests that enhanced interventions are needed to contain the burden of tuberculosis in Botswana and prevent further drug resistance.
A Dartmouth study found that traditional TB screening methods can miss active tuberculosis cases in HIV-positive individuals in developing countries. The study recommends using more sensitive and accurate TB culture tests, such as the one used in Tanzania.
A study found that disease reinfection rates for TB were four times higher than new cases in South Africa. Additionally, researchers discovered that low-dose spiral computer-based tomography (CT) screening can lead to an early diagnosis of lung cancer in a high proportion of cases.
A promising new TB drug, PA-824, has entered human clinical trials, showing activity against both actively dividing and slow-growing M. tb stages. The drug may significantly reduce the time needed to cure TB, offering hope for shorter treatment regimens.
The study found that global new TB cases increased by 1% in 2003, but detection rates improved to 45% by 2003, reaching 60% by 2005. Treatment success rates were over 80% since 1998, with variation among regions.
A blood-based TB test, QuantiFERON-TB-Gold, has been shown to match the results of the traditional tuberculin skin test among Indian healthcare workers. The study found a high level of agreement between the two tests, with only minor impact from previous TB vaccination.
California continues to experience cases of multi-drug resistant tuberculosis (MDR-TB), which requires prolonged treatment and poses significant public health risks. The majority of MDR-TB cases are foreign-born, highlighting the need for international TB control measures.
A study of 546 patients found that chest x-rays are not effective in determining when tuberculosis (TB) was acquired. The researchers discovered that the most significant independent predictor of radiographic appearance is HIV status, indicating altered immunity rather than recent infection.
The US needs more effective treatments for active TB and latent TB infection, with a focus on improving diagnostic tools and directly observed therapy. Effective treatment of active TB requires at least six months of multi-drug therapy, while improved diagnostics and treatments are needed for latent TB infection.
TB is a serious global health issue that affects vulnerable populations, requiring improved screening, treatment, and quality of care. The JAMA editorial highlights the need for better funding and initiatives to combat TB and ultimately eradicate it worldwide.
A study in South Africa found that a new treatment approach, including isoniazid and cotrimoxazole, reduced tuberculosis incidence among HIV-infected employees by 32%. The intervention was part of a clinic established in 1999 to provide specialist care for HIV-infected employees.
A 1994-2003 study analyzed TB cases among homeless and non-homeless persons to identify overlapping risk factors. The study found a higher proportion of TB cases associated with homelessness in western and southern states, with most affected males aged 30-59.
Researchers have discovered a new strategy used by TB bacteria to resist fluoroquinolone antibiotics, which are often ineffective against multi-drug-resistant TB. The discovery also reveals that other disease-causing bacteria, such as Shigella and E. coli, have developed similar resistance mechanisms.
MacMicking studies immune-related GTPases in response to Mycobacterium tuberculosis (Mtb) infection to understand biological relationship between eukaryotes and prokaryotes. The award will support his research program on novel host defense pathways to infection.
Aeras and UCLA announce a license deal for rBCG30, a live recombinant vaccine technology developed at UCLA's David Geffen School of Medicine. The vaccine has shown promising results in initial clinical studies and holds potential to reduce TB disease burden globally.
Researchers discovered a gene, Ipr1, on mouse chromosome 1 that influences innate immunity to tuberculosis and another intracellular pathogen, Listeria monocytogenes. The study suggests that the human equivalent of Ipr1, SP110, may play a significant role in determining tuberculosis susceptibility.
A study of 752 French patients found that shorter graft ischemic times were associated with improved long-term survival after single or double lung transplantation. The median ischemic time was 240 minutes, and a cutoff time of 330 minutes was identified as best discriminating between survivors and non-survivors.
A five-year study in Mexico found that the Directly Observed Therapy (DOTS) strategy significantly reduced drug-resistant TB transmission. The results showed a decline from 22% to 7.8% of new patients carrying drug-resistant strains, with no cases of multiple-drug resistance.
A study in Southern Mexico found that implementing DOTS (short-course chemotherapy) significantly reduced the incidence of drug-resistant tuberculosis, from 9.4 to 1.5 cases per 100,000 people between 1996 and 2000. The strategy also improved treatment outcomes for patients with drug-resistant TB.
Researchers have identified a missing enzyme in M. tuberculosis that plays a crucial role in the bacterium's ability to acquire iron through mycobactin synthesis. This discovery highlights the importance of understanding the iron scavenging pathway in TB and provides new avenues for developing effective anti-TB drugs.
Researchers at the University of Pennsylvania School of Medicine identified a biochemical target that could lead to a new class of antibiotics to fight TB. They found that inhibiting an enzyme in a common biochemical pathway can stop the bacteria from multiplying and eventually kill them.
Countries like Canada, USA, Australia, and New Zealand have adopted stringent policies for compulsory screening of new entrants for TB and HIV. However, UK public inquiry concluded that such a policy would not be effective at protecting public health.
Researchers have developed an efficient new strategy to synthesize a natural marine product with promising anti-tuberculosis activity, overcoming challenges of conventional chemistry. The breakthrough enables the production of gram quantities in just days, paving the way for developing potential anti-inflammatory and anticancer agents.
A collaborative study found evidence of TB and leprosy co-infection in ancient bones across Europe, suggesting that TB overtook leprosy as a more aggressive disease. The findings imply that the decline of leprosy may have been linked to the rise of TB, which brought a speedier death due to opportunistic co-infection.
A simple sputum test has been developed to confirm childhood tuberculosis diagnosis in infants and young children. The test uses sputum induction, which was found to be effective even in young infants, with almost 40% of children under one year of age having a positive culture.
A recent study found that patients with previously untreated HIV-1 infection, especially those co-infected with pulmonary TB or KS, showed rapid responses to triple-drug therapy. After three months, nearly all patients achieved undetectable HIV RNA levels and experienced significant increases in CD4 cell counts.
A large retrospective study found that tuberculosis incidence doubled within the first year of HIV infection and increased four-fold after two years. The study's unique setting, including a high incidence of tuberculosis among miners and access to free healthcare, facilitated the research.
R207910, a novel diarylquinoline compound, has demonstrated effectiveness in clearing infection from lungs of mice and reducing bacterial load by 50%. The drug's unique mechanism of action targeting ATP synthase makes it active against drug-resistant strains of TB.
A new antibiotic shows promise in treating tuberculosis by shortening treatment time and fighting drug-resistant strains. The drug, called R207910, operates differently than other antibiotics and appears to inhibit the bacteria's energy supply.
A clinical study found that roughly half the population produces more than 98% of potentially pathogenic bioaerosols. Administration of nebulized saline can reduce droplet exhalation in high-producers for up to six hours.
Researchers found that thrice weekly versus daily drug therapy regimens were associated with a higher risk of disease relapse in tuberculosis patients. The study analyzed data from over 12,000 patients who completed treatment between 1998 and 2000.
The Oregon Health & Science University will focus on tuberculosis research, using cells from TB patients with successful immune responses to create vaccines. The goal is to provide protection to others while over 2 million people die worldwide each year of TB.
Researchers have discovered a way to disable TB protein when it binds to certain molecules, making bacteria more sensitive to treatment by ethionamide. This finding suggests that combining ethionamide with benzylacetone could reduce the dosage of potent antibacterial compounds and improve TB treatment.
A US study found a significant link between exposure to traffic pollutants and an increased risk of bronchitis or physician-diagnosed asthma in children. In contrast, directly observed therapy for tuberculosis patients showed a significantly higher cure rate compared to self-administered therapy.
A study found prednisolone to be ineffective in treating HIV-associated pleural tuberculosis, increasing the risk of life-threatening cancer. The drug improved symptoms but showed no long-term benefits for patients without HIV infection.
Researchers found that a high-fiber diet from fruits and soy foods reduces the incidence of chronic respiratory symptoms, particularly cough with phlegm production. Additionally, brief exposure to multidrug-resistant tuberculosis can lead to infection, as detected by rapid molecular testing in hospital contacts.
A survey in 2000 showed a decrease in tuberculosis prevalence of around a third compared to the original survey in 1990. China aims to reach the UN Millennium Development Goal of halving TB prevalence between 2000 and 2015 with its expansion plans.
A new study found that almost 60% of children with asthma during the pre-pubertal period continue to experience wheezing episodes after the onset of puberty. Obesity at age 11 was also associated with a threefold increased risk for persistence of asthma, according to researchers analyzing data from a longitudinal birth cohort.
The Global Fund's performance-based payment system is challenging for recipients and sub-recipients to meet, hindering disease control intervention scaling-up. Experts call for clearer guidelines, improved coordination among donors, and simpler funding systems to achieve the Fund's goals.
Researchers created a virtual model of the human immune system to study M. tuberculosis, a bacterium that causes TB. The computer model revealed key findings on granuloma formation and the immune response, shedding light on why some people fight off infection while others get sick.
A recent study suggests that surgery provides a favorable outcome for long-term multidrug-resistant tuberculosis patients. The surgeons at the National Jewish Medical and Research Center have extensive experience in treating mycobacterial lung disease, making them uniquely qualified to assess individual patient risk/benefit balances.
Researchers have detailed the workings of a key enzyme in tuberculosis bacteria's cell walls, which could lead to the development of new antibiotics. By understanding how this enzyme works, scientists can design inhibitors specific to it, potentially creating new treatments for TB and leprosy.
A team of chemists from the University of Wisconsin-Madison has identified a key enzyme essential for the bacteria that cause tuberculosis. Disrupting this enzyme could lead to the development of a new family of antibiotics, providing hope for millions of people affected by multidrug-resistant TB.
A consortium has launched a programme to develop a TB vaccine, with the Max Planck Institute for Infection Biology developing a highly promising candidate. The vaccine aims to improve upon the existing BCG vaccine, which lacks effectiveness against pneumotuberculosis.
The collaboration aims to improve the BCG vaccine, which offers protection against serious forms of TB in childhood but loses efficacy over time. A new vaccine is crucial to combating the disease that kills over two million people globally per year.
Researchers used gene chips to analyze the pattern of gene-expression changes for tuberculosis in a living host, discovering a specific set of genes activated after 21 days post-infection. This indicates that these genes help the pathogen survive within the host while avoiding detection by the immune system.
The study reveals that people from different regions carry distinct strains of the tuberculosis bacteria, indicating sociological interactions play a key role in transmission. This finding has significant implications for vaccine development, potentially leading to region-specific vaccines.
The World Health Organization's (WHO) global tuberculosis control strategy, DOTS, is facing challenges in meeting its 2005 targets. A significant case-detection gap exists between estimated annual incident cases and reported cases under the DOTS strategy. The WHO recommends four key actions to address this issue, including equipping na...
A new study found that multiple Mycobacterium tuberculosis strains are present in patients with active TB, contradicting the long-held theory of a single strain. Additionally, researchers developed a method to isolate and quantify airborne TB aerosols from coughs, showing promise for studying the disease's transmission.
A new TB vaccine, rBCG30, is being tested in a human clinical trial to assess its safety and immune response. The vaccine, developed by Dr. Marcus Horwitz and his team at UCLA, has shown promise in preclinical trials and could potentially reduce the TB disease burden worldwide.
The Gates Foundation has committed $82.9 million to develop new tuberculosis vaccines, with the goal of creating a more effective vaccine within 10 years. The grant will support research in three major areas: vaccine trials, improved animal models, and next-generation vaccines.
The Netherlands has established two new research centers, NIVAREC and PRIOR, to develop and produce flu vaccines and tackle poverty-related infectious diseases. The centers aim to strengthen cooperation between researchers from different institutes and foster knowledge infrastructure in developing countries.
A $4 million grant aims to conserve Papua New Guinea's rainforest by discovering medicinal plants. The project seeks compounds active against tuberculosis, HIV, malaria, and cancer, with the goal of providing economic development and biodiversity conservation.
A new recombinant tuberculosis vaccine is being tested in a Phase I clinical trial in the United States, combining two proteins known to stimulate strong immune responses in humans. The vaccine aims to offer protection against pulmonary TB, the most contagious form of the disease.
The University of California - San Diego Medical Center has been awarded a contract by the NIH to create a national tuberculosis educational curriculum. The goal is to raise awareness and improve education on TB, which can be controlled with effective medications. The consortium includes faculty members from 12 medical schools, six nur...
This year's Wakley Prize essays share personal reflections from doctors and patients in Peru, highlighting the struggle to tackle tuberculosis despite financial constraints. The essays reveal how poverty draws a line between life and death for many individuals.
Researchers found that a gene mutation led to a more deadly strain of tuberculosis, which spread rapidly in mice and caused increased bacterial load in organs. The mutated bacteria were able to evade the host's immune system, leading to severe infection and death.
A prospective study in Botswana found that only 1.8% of asymptomatic HIV-infected outpatients with preventive therapy developed TB, rendering routine chest radiography unnecessary for screening in settings where signs and symptoms can be effectively identified.
A new TB vaccine, using a killed Mycobacterium vaccae vaccine, has shown to enhance immunity against TB in both HIV-positive and negative patients. The study, conducted in Finland and Tanzania, suggests the vaccine may be an effective tool in preventing TB among high-risk populations.